Bonus Biogroup (Israel) Top Management
| BONS Stock | ILS 16.60 0.30 1.78% |
Bonus Biogroup employs about 13 people. The company is managed by 13 executives with a total tenure of roughly 116 years, averaging almost 8.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Bonus Biogroup's management performance can provide insight into the company performance.
| Shai Meretzki CEO CEO and Presidentident, Director |
| Joseph Rauch Chairman Chairman of the Board, Vice President - Business Development |
Bonus |
Bonus Biogroup Management Team Effectiveness
The company has return on total asset (ROA) of (0.0636) % which means that it has lost $0.0636 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5522) %, meaning that it generated substantial loss on money invested by shareholders. Bonus Biogroup's management efficiency ratios could be used to measure how well Bonus Biogroup manages its routine affairs as well as how well it operates its assets and liabilities.Bonus Biogroup Workforce Comparison
Bonus Biogroup is number one stock in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 40,436. Bonus Biogroup adds roughly 13.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Bonus Biogroup Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Bonus Biogroup Price Series Summation is a cross summation of Bonus Biogroup price series and its benchmark/peer.
Bonus Biogroup Notable Stakeholders
A Bonus Biogroup stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bonus Biogroup often face trade-offs trying to please all of them. Bonus Biogroup's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bonus Biogroup's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Shai Meretzki | CEO and Presidentident, Director | Profile | |
| Joseph Rauch | Chairman of the Board, Vice President - Business Development | Profile | |
| Yosef Rauch | Chairman of the Board, Vice President - Business Development | Profile | |
| Yehonatan Livne | CFO | Profile | |
| Gil Shapira | Director | Profile | |
| Daniel BenLulu | Director | Profile | |
| Avi Slonim | External Director | Profile | |
| Yehuda Reznik | Director | Profile | |
| Rachel Ari | Director | Profile | |
| Batia Avital | Director | Profile | |
| Vered Kivity | Head Affairs | Profile | |
| Yoni CPA | Chief Officer | Profile | |
| Joseph MBA | Ex Chairman | Profile |
About Bonus Biogroup Management Performance
The success or failure of an entity such as Bonus Biogroup often depends on how effective the management is. Bonus Biogroup management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bonus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bonus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. Bonus BioGroup Ltd., formerly known as Oceana Advanced Industries Ltd., was founded in 1981 and is based in Haifa, Israel. BONUS BIOGROUP is traded on Tel Aviv Stock Exchange in Israel.
The data published in Bonus Biogroup's official financial statements usually reflect Bonus Biogroup's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Bonus Biogroup. For example, before you start analyzing numbers published by Bonus accountants, it's critical to develop an understanding of what Bonus Biogroup's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Bonus Biogroup's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bonus Biogroup's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Bonus Biogroup's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bonus Biogroup. Please utilize our Beneish M Score to check the likelihood of Bonus Biogroup's management manipulating its earnings.
Bonus Biogroup Workforce Analysis
Traditionally, organizations such as Bonus Biogroup use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bonus Biogroup within its industry.Bonus Biogroup Manpower Efficiency
Return on Bonus Biogroup Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 6.9M | |
| Net Loss Per Executive | 6.9M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bonus Biogroup. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Bonus Stock analysis
When running Bonus Biogroup's price analysis, check to measure Bonus Biogroup's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bonus Biogroup is operating at the current time. Most of Bonus Biogroup's value examination focuses on studying past and present price action to predict the probability of Bonus Biogroup's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bonus Biogroup's price. Additionally, you may evaluate how the addition of Bonus Biogroup to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |